Veeva vs Salesforce - the services questions that Life Sciences organizations need to be asking - and time is running out

As noted previously, when Veeva ended its licence agreement with Salesforce, it not only triggered a battle royale for domination of big pharma CRM, it began the first massive use case for adoption of agentic AI. Customers have to decide whether to move to Veeva’’s new platform Veeva Vault CRM, or to Salesforce’s new Life Sciences (LS) Cloud.

Whichever choice existing Veeva customers make they are facing a big migration project to a new agentic platform. They have until September 2030 to make the move. This is creating a resourcing challenge for the Salesforce SIs working in pharma, as well as offering them the first real big industrial step-change amongst clients towards agentic AI.

The pharma CRM migration begins

I recently had the chance to discuss this with Erica Adams, Human Capital Salesforce Director at Deloitte. She explains:

Over the past quarter I’ve been very busy working ...